Health Care & Life Sciences » Biotechnology | ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,145.00
120.00
61.00
17,331.00
124,901.00
223,807
Cost of Goods Sold (COGS) incl. D&A
-
-
-
3,075.00
9,077.00
12,377
Gross Income
-
-
-
14,256.00
115,824.00
211,430
SG&A Expense
39,363.00
93,144.00
161,526.00
285,740.00
404,251.00
458,874
EBIT
38,297.00
93,230.00
164,612.00
272,815.00
292,410.00
247,444
Pretax Income
37,948.00
92,475.00
164,113.00
270,052.00
288,284.00
243,936
Income Tax
-
-
330.00
1,341.00
1,119.00
1,256
Consolidated Net Income
37,948.00
92,475.00
164,443.00
271,393.00
289,403.00
245,192
Net Income
37,948.00
92,475.00
164,443.00
271,393.00
289,403.00
245,192
Net Income After Extraordinaries
37,948.00
92,475.00
164,443.00
271,393.00
289,403.00
245,192
Net Income Available to Common
37,948.00
92,475.00
164,443.00
271,393.00
289,403.00
245,192
EPS (Basic)
0.44
0.95
1.63
2.34
2.36
1.94
Basic Shares Outstanding
85,715.00
97,248.00
100,630.00
115,858.00
122,600.00
126,583
EPS (Diluted)
0.44
0.95
1.63
2.34
2.36
1.94
Diluted Shares Outstanding
85,715.00
97,248.00
100,630.00
115,858.00
122,600.00
126,583
EBITDA
38,218.00
93,024.00
163,965.00
270,987.00
289,697.00
244,439
Other Operating Expense
-
-
2,500.00
1,331.00
3,983.00
-
Non-Operating Interest Income
349.00
755.00
499.00
2,763.00
4,126.00
5,348

About ACADIA Pharmaceuticals

View Profile
Address
3611 Valley Centre Drive
San Diego California 92130
United States
Employees -
Website http://www.acadia-pharm.com
Updated 07/08/2019
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment. The company was founded by Mark R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.